Masuda F, Nakada J, Kondo I, Furuta N
Department of Urology, Daisan Hospital, Jikei University School of Medicine, Tokyo, Japan.
Cancer Chemother Pharmacol. 1992;30(6):477-9. doi: 10.1007/BF00685600.
VAU therapy (vinblastine, Adriamycin, and UFT) was given postoperatively to 31 patients with stage I, II, or III renal-cell carcinoma, and the incidence of relapse as well as the survival of patients were studied. Administration was started at 7-14 days post-surgery; 5 mg/m2 vinblastine and 30 mg/m2 Adriamycin were given i.v. once every 4 weeks for a total of five courses, and three capsules of UFT (containing 300 mg tegafur) were given p.o. every day for 2-3 years. The postoperative observation period ranged from 2 years and 6 months to 7 years and 1 month (mean, 4 years and 2 months). The 1-year survival of patients was 100%, and the 3- and 5-year survival values were 96%. These results were significantly better (P less than 0.01) than the respective values (81%, 72%, and 60%) obtained for the historical controls, i.e., the 60 patients with stage I, II, or III renal-cell carcinoma who received no chemotherapy. Side effects such as alopecia, gastrointestinal symptoms, and myelosuppression were encountered, but all symptoms were so mild and transient that discontinuation of the treatment was not necessary. As VAU therapy might be useful as adjuvant chemotherapy for renal-cell carcinoma, it seems to merit further study.
对31例I、II或III期肾细胞癌患者术后给予VAU疗法（长春碱、阿霉素和优福定），并研究患者的复发率和生存率。给药于术后7 - 14天开始；静脉注射5mg/m²长春碱和30mg/m²阿霉素，每4周1次，共5个疗程，口服优福定胶囊3粒（含替加氟300mg），每日1次，持续2 - 3年。术后观察期为2年6个月至7年1个月（平均4年2个月）。患者1年生存率为100%，3年和5年生存率分别为96%。这些结果明显优于历史对照（即60例未接受化疗的I、II或III期肾细胞癌患者）的相应值（81%、72%和60%）（P < 0.01）。出现了脱发、胃肠道症状和骨髓抑制等副作用，但所有症状都很轻微且短暂，无需中断治疗。由于VAU疗法可能作为肾细胞癌的辅助化疗有效，似乎值得进一步研究。
